Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Nov;59(Suppl 1):i72–i74. doi: 10.1136/ard.59.suppl_1.i72

The final pathogenetic steps in focal bone erosions in rheumatoid arthritis

S Goldring
PMCID: PMC1766621  PMID: 11053093

Full Text

The Full Text of this article is available as a PDF (76.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bresnihan B., Alvaro-Gracia J. M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998 Dec;41(12):2196–2204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  2. Bromley M., Fisher W. D., Woolley D. E. Mast cells at sites of cartilage erosion in the rheumatoid joint. Ann Rheum Dis. 1984 Feb;43(1):76–79. doi: 10.1136/ard.43.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bromley M., Woolley D. E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984 Sep;27(9):968–975. doi: 10.1002/art.1780270902. [DOI] [PubMed] [Google Scholar]
  4. Bromley M., Woolley D. E. Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum. 1984 Aug;27(8):857–863. doi: 10.1002/art.1780270804. [DOI] [PubMed] [Google Scholar]
  5. Chu C. Q., Field M., Allard S., Abney E., Feldmann M., Maini R. N. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol. 1992 Oct;31(10):653–661. doi: 10.1093/rheumatology/31.10.653. [DOI] [PubMed] [Google Scholar]
  6. Deleuran B. W., Chu C. Q., Field M., Brennan F. M., Katsikis P., Feldmann M., Maini R. N. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 1992 Dec;31(12):801–809. doi: 10.1093/rheumatology/31.12.801. [DOI] [PubMed] [Google Scholar]
  7. Deodhar A. A., Woolf A. D. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol. 1996 Apr;35(4):309–322. doi: 10.1093/rheumatology/35.4.309. [DOI] [PubMed] [Google Scholar]
  8. Eggelmeijer F., Papapoulos S. E., van Paassen H. C., Dijkmans B. A., Valkema R., Westedt M. L., Landman J. O., Pauwels E. K., Breedveld F. C. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 1996 Mar;39(3):396–402. doi: 10.1002/art.1780390307. [DOI] [PubMed] [Google Scholar]
  9. Feldmann M., Brennan F. M., Maini R. N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397. [DOI] [PubMed] [Google Scholar]
  10. Funk J. L., Cordaro L. A., Wei H., Benjamin J. B., Yocum D. E. Synovium as a source of increased amino-terminal parathyroid hormone-related protein expression in rheumatoid arthritis. A possible role for locally produced parathyroid hormone-related protein in the pathogenesis of rheumatoid arthritis. J Clin Invest. 1998 Apr 1;101(7):1362–1371. doi: 10.1172/JCI484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goldring S. R., Gravallese E. M. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res. 1999 Dec 22;2(1):33–37. doi: 10.1186/ar67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goldring S. R., Gravallese E. M. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 2000 May;12(3):195–199. doi: 10.1097/00002281-200005000-00006. [DOI] [PubMed] [Google Scholar]
  13. Gorn A. H., Rudolph S. M., Flannery M. R., Morton C. C., Weremowicz S., Wang T. Z., Krane S. M., Goldring S. R. Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction. J Clin Invest. 1995 Jun;95(6):2680–2691. doi: 10.1172/JCI117970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gough A. K., Peel N. F., Eastell R., Holder R. L., Lilley J., Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis. 1994 Jan;53(1):14–17. doi: 10.1136/ard.53.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gravallese E. M., Harada Y., Wang J. T., Gorn A. H., Thornhill T. S., Goldring S. R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol. 1998 Apr;152(4):943–951. [PMC free article] [PubMed] [Google Scholar]
  16. Gravallese E. M., Manning C., Tsay A., Naito A., Pan C., Amento E., Goldring S. R. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000 Feb;43(2):250–258. doi: 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  17. Hattersley G., Chambers T. J. Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology. 1989 Sep;125(3):1606–1612. doi: 10.1210/endo-125-3-1606. [DOI] [PubMed] [Google Scholar]
  18. Hattersley G., Chambers T. J. Generation of osteoclastic function in mouse bone marrow cultures: multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. Endocrinology. 1989 Apr;124(4):1689–1696. doi: 10.1210/endo-124-4-1689. [DOI] [PubMed] [Google Scholar]
  19. Haugeberg G., Uhlig T., Falch J. A., Halse J. I., Kvien T. K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000 Mar;43(3):522–530. doi: 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  20. Hooyman J. R., Melton L. J., 3rd, Nelson A. M., O'Fallon W. M., Riggs B. L. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum. 1984 Dec;27(12):1353–1361. doi: 10.1002/art.1780271205. [DOI] [PubMed] [Google Scholar]
  21. Horwood N. J., Kartsogiannis V., Quinn J. M., Romas E., Martin T. J., Gillespie M. T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999 Nov;265(1):144–150. doi: 10.1006/bbrc.1999.1623. [DOI] [PubMed] [Google Scholar]
  22. Hummel K. M., Petrow P. K., Franz J. K., Müller-Ladner U., Aicher W. K., Gay R. E., Brömme D., Gay S. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol. 1998 Oct;25(10):1887–1894. [PubMed] [Google Scholar]
  23. Joosten L. A., Helsen M. M., Saxne T., Heinegård D., van de Putte L. B., van den Berg W. B. Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis. Inflamm Res. 1999 Jan;48(1):48–55. doi: 10.1007/s000110050396. [DOI] [PubMed] [Google Scholar]
  24. Joosten L. A., Helsen M. M., van de Loo F. A., van den Berg W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996 May;39(5):797–809. doi: 10.1002/art.1780390513. [DOI] [PubMed] [Google Scholar]
  25. Kong Y. Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999 Nov 18;402(6759):304–309. doi: 10.1038/46303. [DOI] [PubMed] [Google Scholar]
  26. Kröger H., Arnala I., Alhava E. M. Effect of calcitonin on bone histomorphometry and bone metabolism in rheumatoid arthritis. Calcif Tissue Int. 1992 Jan;50(1):11–13. doi: 10.1007/BF00297290. [DOI] [PubMed] [Google Scholar]
  27. Kuratani T., Nagata K., Kukita T., Hotokebuchi T., Nakasima A., Iijima T. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol. 1998 Jul;13(3):751–759. doi: 10.14670/HH-13.751. [DOI] [PubMed] [Google Scholar]
  28. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998 Apr 17;93(2):165–176. doi: 10.1016/s0092-8674(00)81569-x. [DOI] [PubMed] [Google Scholar]
  29. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  30. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  31. Okano K., Tsukazaki T., Ohtsuru A., Namba H., Osaki M., Iwasaki K., Yamashita S. Parathyroid hormone-related peptide in synovial fluid and disease activity of rheumatoid arthritis. Br J Rheumatol. 1996 Nov;35(11):1056–1062. doi: 10.1093/rheumatology/35.11.1056. [DOI] [PubMed] [Google Scholar]
  32. Ralston S. H., Hacking L., Willocks L., Bruce F., Pitkeathly D. A. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis. 1989 May;48(5):396–399. doi: 10.1136/ard.48.5.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Romas E., Bakharevski O., Hards D. K., Kartsogiannis V., Quinn J. M., Ryan P. F., Martin T. J., Gillespie M. T. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000 Apr;43(4):821–826. doi: 10.1002/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  34. Sambrook P. N., Ansell B. M., Foster S., Gumpel J. M., Hesp R., Reeve J. Bone turnover in early rheumatoid arthritis. 2. Longitudinal bone density studies. Ann Rheum Dis. 1985 Sep;44(9):580–584. doi: 10.1136/ard.44.9.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sambrook P. N., Eisman J. A., Champion G. D., Yeates M. G., Pocock N. A., Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum. 1987 Jul;30(7):721–728. doi: 10.1002/art.1780300701. [DOI] [PubMed] [Google Scholar]
  36. Sambrook P. N., Eisman J. A., Yeates M. G., Pocock N. A., Eberl S., Champion G. D. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis. 1986 Nov;45(11):950–953. doi: 10.1136/ard.45.11.950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sharp J. T., Strand V., Leung H., Hurley F., Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000 Mar;43(3):495–505. doi: 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  38. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309–319. doi: 10.1016/s0092-8674(00)80209-3. [DOI] [PubMed] [Google Scholar]
  39. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999 Nov 22;159(21):2542–2550. doi: 10.1001/archinte.159.21.2542. [DOI] [PubMed] [Google Scholar]
  40. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., Koshihara Y., Oda H., Nakamura K., Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000 Feb;43(2):259–269. doi: 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  41. Wong B. R., Josien R., Lee S. Y., Sauter B., Li H. L., Steinman R. M., Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997 Dec 15;186(12):2075–2080. doi: 10.1084/jem.186.12.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Wong B. R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F. S., 3rd, Frankel W. N. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997 Oct 3;272(40):25190–25194. doi: 10.1074/jbc.272.40.25190. [DOI] [PubMed] [Google Scholar]
  43. Yamin M., Gorn A. H., Flannery M. R., Jenkins N. A., Gilbert D. J., Copeland N. G., Tapp D. R., Krane S. M., Goldring S. R. Cloning and characterization of a mouse brain calcitonin receptor complementary deoxyribonucleic acid and mapping of the calcitonin receptor gene. Endocrinology. 1994 Dec;135(6):2635–2643. doi: 10.1210/endo.135.6.7988453. [DOI] [PubMed] [Google Scholar]
  44. Yasuda H., Shima N., Nakagawa N., Mochizuki S. I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998 Mar;139(3):1329–1337. doi: 10.1210/endo.139.3.5837. [DOI] [PubMed] [Google Scholar]
  45. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597–3602. doi: 10.1073/pnas.95.7.3597. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES